ABSTRACT
The BONN Risk Index (BRI) successfully determines the calcium oxalate (CaOx) crystallization risk from urine samples. The BRI is based on a standardized crystallization test performed on native urine. A BRI-measuring device, the "Urolizer", has been developed, operating automatically and requiring only a minimum of preparative efforts. In this study, the Urolizer is evaluated regarding its analytical and diagnostic practicability for metaphylaxis control in the framework of the daily routine of a stone surgery. From 51 CaOx recurrent stone-formers, 24 h urines were collected at the beginning and after 3 months of metaphylaxis. As much as 27 patients were indicated to suffer from "mild hypercalciuria", low urinary pH or hypocitraturia, and 24 patients from "hypercalciuria". The former were treated with alkaline citrate (AC), and the latter with hydrochlorothiazide (HCT). Analyses of urines collected before and during treatment, BRI using the Urolizer, and urinalysis-based risk indices were evaluated. In both patient groups, BRI decreased significantly, while metaphylaxis (P<0.001) in the AC group decreased from 1.08 (+/-0.58) to 0.56 (+/-0.39) L(-1) and in the HCT-group from 3.30 (+/-1.15) to 1.60 (+/-0.52) L(-1). In most patients, urinary parameters changed as desired and related risk indices decreased appropriately. The clinical utility of the easy-to-determine BRI is demonstrated. By quantifying the "overall" therapy effect within 15 min, the innovative analysis device may be especially suited for practitioners specializing in urolithiasis treatment.
Subject(s)
Calcium Oxalate/metabolism , Urolithiasis/metabolism , Adult , Aged , Calcium Oxalate/chemistry , Calcium Oxalate/urine , Citric Acid/therapeutic use , Crystallization , Female , Humans , Hydrochlorothiazide/therapeutic use , Hydrogen-Ion Concentration , Hypercalciuria/drug therapy , Hypercalciuria/urine , Linear Models , Male , Middle Aged , Models, Biological , Recurrence , Risk Factors , Urolithiasis/drug therapy , Urolithiasis/etiology , Urolithiasis/urineABSTRACT
BACKGROUND: Since its first publication in 2000, the BONN-Risk-Index (BRI) has been successfully used to determine the calcium oxalate (CaOx) crystallization risk from urine samples. To date, a BRI-measuring device, the "Urolizer", has been developed, operating automatically and requiring only a minimum of preparation. Two major objectives were pursued: determination of Urolizer precision, and determination of the influence of 24-h urine storage at moderate temperatures on BRI. METHODS: 24-h urine samples from 52 CaOx stone-formers were collected. A total of 37 urine samples were used for the investigation of Urolizer precision by performing six independent BRI determinations in series. In total, 30 samples were taken for additional investigation of urine storability. Each sample was measured thrice: directly after collection, after 24-h storage at T=21 degrees C, and after 24-h cooling at T=4 degrees C. Outcomes were statistically tested for identity with regard to the immediately obtained results. RESULTS: Repeat measurements for evaluation of Urolizer precision revealed statistical identity of data (p-0.05). 24-h storage of urine at both tested temperatures did not significantly affect BRI (p-0.05). CONCLUSIONS: The pilot-run Urolizer shows high analytical reliability. The innovative analysis device may be especially suited for urologists specializing in urolithiasis treatment. The possibility for urine storage at moderate temperatures without loss of analysis quality further demonstrates the applicability of the BRI method.
